source
- FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic CarcinomaEmi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.onclive · 2mo ago↗ source
- [177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.onclive · 2mo ago↗ source
- FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid SarcomaThe FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.onclive